Prospective evaluation of the safety and efficacy of microwave ablation for hepatocellular carcinoma in Korean patients
Authors:
- Min Woo LeeMLMin Woo Lee
- Hyunchul RhimHRHyunchul Rhim
- Seong Hyun KimSKSeong Hyun Kim
- Kyoung Doo SongKSKyoung Doo Song
- Tae Wook KangTKTae Wook Kang
- Joon Hyeok LeeJLJoon Hyeok Lee
- Won Seok KangWKWon Seok Kang
- Jaclyn StanziolaJSJaclyn Stanziola
- Abdullah MamunAMAbdullah Mamun
- Hector De LeonHLHector De Leon
- Erin Elyse MeyersEMErin Elyse Meyers
Open Access
- 1 January 2026
- journal article
- Published by Korean Society of Ultrasound in Medicine in Ultrasonography
- Vol. 45 (1) , 59-68
Abstract
Purpose: This study evaluated the 3-year safety and efficacy of microwave ablation (MWA) as an alternative to radiofrequency ablation in Korean patients with hepatocellular carcinoma (HCC).Methods: In this prospective single-center study, 33 adults with a single HCC lesion (2–5 cm; Barcelona Clinic Liver Cancer stage A) were enrolled between December 2017 and May 2020. All underwent ultrasound-guided MWA using the NEUWAVE system. One patient did not complete post-treatment evaluation and two had protocol deviations, yielding a full analysis set of 30 patients and a safety analysis set of 33 patients. Study endpoints included technical success (TS), technique efficacy (TE), local tumor progression (LTP), overall survival (OS), and adverse events (AEs) over a 3-year follow-up period.Results: All 33 patients were included in the safety analysis, while 30 were included in the efficacy analysis. Most patients were male (83.3%), with a median age of 64 years and a mean tumor size of 2.5±0.6 cm. Median follow-up was 36.2 months. TS and TE were achieved in all cases. The 3-year cumulative LTP rate was 7.3%, and the 3-year OS rate was 90.0%. Minor AEs occurred in 54.5% of patients, most commonly post-ablation pain and fever. Two patients (6.1%) experienced major AEs, including pyrexia and duodenal thermal injury. No procedure- or device-related deaths occurred.Conclusion: MWA appears to be a safe and effective treatment for early-stage HCC, demonstrating durable tumor control and a low incidence of major complications over 3 years.Keywords
This publication has 22 references indexed in Scilit:
- BCLC strategy for prognosis prediction and treatment recommendation: The 2022 updateJournal of Hepatology, 2021
- Efficacy of microwave ablation versus radiofrequency ablation for hepatocellular carcinoma: a propensity score analysisAbdominal Radiology, 2021
- Small single perivascular hepatocellular carcinoma: comparisons of radiofrequency ablation and microwave ablation by using propensity score analysisEuropean Radiology, 2021
- Prospective double-blinded randomized controlled trial of Microwave versus RadioFrequency Ablation for hepatocellular carcinoma (McRFA trial)HPB, 2020
- Local and Regional Therapies for Hepatocellular CarcinomaHepatology, 2020
- Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma < 3 cm: emphasis on association of local tumor progression and overall survivalEuropean Radiology, 2020
- Comparison of no-touch multi-bipolar vs. monopolar radiofrequency ablation for small HCCJournal of Hepatology, 2017
- Preliminary Outcome of Microwave Ablation of Hepatocellular Carcinoma: Breaking the 3-cm Barrier?Journal of Vascular and Interventional Radiology, 2016
- Percutaneous Microwave Ablation of Hepatic Tumors: Prospective Evaluation of Postablation Syndrome and Postprocedural PainJournal of Vascular and Interventional Radiology, 2014
- Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: Analysis of prognostic factorsJournal of Hepatology, 2013